Capture the Rapidly Growing Comprehensive Nutritional Infusion Market... New Products Released One After Another

Infusion Solution Market Expands Due to Aging Population and Increase in Chronic Disease Patients
HK Innoen and Baxter Launch New Products to Secure Competitiveness

As the total parenteral nutrition (TPN) market expands, new products containing high concentrations of ingredients are being launched, intensifying competition.

Total parenteral nutrition is a functional infusion that supplies the three major nutrients via intravenous injection to patients who cannot ingest food orally. The domestic market is gradually expanding due to aging and an increase in chronic disease patients. It recorded 135.4 billion KRW in 2021, 138.1 billion KRW in 2022, and 180 billion KRW in 2023, showing growth every year. The pharmaceutical industry expects the market to reach the 200 billion KRW range this year. Typically, infusion sales increase as the number of hospital beds and patient hospitalization days increase. Unlike basic infusions, which are recognized by health insurance with minimal margins, total parenteral nutrition is a non-reimbursed drug and generally shows a sales profit margin of over 50%.

According to IMS data, a pharmaceutical market research firm, on the 13th, JW Pharmaceutical’s products held the highest market share in the total parenteral nutrition market in 2022, while Germany’s Fresenius Kabi’s TPN SmofKabiven (19.5%) and the world’s number one infusion company, the US-based Baxter’s Olimel (13.7%), have been rapidly closing the gap. Following them are domestic pharmaceutical companies HK inno.N’s Omaf One with 8.2% and Yuhan Corporation’s Forms with 2.6%.

Along with the expansion of the total parenteral nutrition market, new products aimed at securing competitiveness are being released one after another. Representative examples include HK inno.N’s Omaf Plus One series and Baxter’s Olimel N12E.

HK inno.N recently launched two products, Omaf Plus One Injection and Omaf Plus One Perri Injection, which have increased omega-3 ratios, aggressively targeting the TPN market. The Omaf Plus One series increases the omega-3 ratio and balances the omega-6 to omega-3 ratio at 1:1, enabling balanced fat supply. It is expected to help improve inflammation and enhance immune function in critically ill or postoperative patients.

HK inno.N secured exclusive rights until January 2039 through patent registration of the composition of the Omaf Plus One series. Leveraging the differentiated competitiveness of the Omaf Plus One series, the company plans to increase its market share in the TPN market.

Global pharmaceutical company Baxter newly launched Olimel N12E, a high-protein nutritional infusion for critically ill patients, in October last year. Olimel N12E contains 76g of amino acids and 950 kcal of energy per 1000 ml. Compared to Baxter’s existing product Olimel N9E, it contains 33% more protein (per 1000 ml), providing sufficient amino acids to patients receiving treatment. The company stated that the appropriate amount of calories and protein contributes to reducing mortality in critically ill patients. Additionally, it offers convenience by providing volume options of 650 ml, 1000 ml, 1500 ml, and 2000 ml, allowing selection of the appropriate infusion volume to supply nutrition tailored to the patient.